Philipp M Roessner
Overview
Explore the profile of Philipp M Roessner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arseni L, Sigismondo G, Yazdanparast H, Hermansen J, Mack N, Ohl S, et al.
Nat Commun
. 2025 Jan;
16(1):1041.
PMID: 39863584
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model...
2.
Tian X, Esmaeili H, Minich D, Seitz F, Roessner P, Wind S, et al.
Pharmacotherapy
. 2024 Dec;
45(2):94-103.
PMID: 39727284
Introduction: Zongertinib (BI 1810631) is a potent, selective, and epidermal growth factor receptor (EGFR) wild-type sparing human epidermal growth factor receptor 2 (HER2) inhibitor. Based on in vitro data, the...
3.
Brinkmann B, Floerchinger A, Schniederjohann C, Roider T, Coelho M, Mack N, et al.
Blood
. 2024 May;
144(7):784-789.
PMID: 38805637
Relapse after anti-CD19 chimeric antigen receptor (CD19-CAR) occurs in a substantial proportion of patients with lymphoid malignancies. We assessed the potential benefits of co-administering CD20-targeting bispecific antibodies (CD20-BsAbs) with CD19-CAR...
4.
Roessner P, Seufert I, Chapaprieta V, Jayabalan R, Briesch H, Massoni-Badosa R, et al.
Blood
. 2024 Apr;
144(5):510-524.
PMID: 38684038
The T-box transcription factor T-bet is known as a master regulator of the T-cell response but its role in malignant B cells has not been sufficiently explored. Here, we conducted...
5.
Pagano G, Fernandez Botana I, Wierz M, Roessner P, Ioannou N, Zhou X, et al.
Haematologica
. 2023 Jun;
108(11):3011-3024.
PMID: 37345470
Chronic lymphocytic leukemia (CLL) cells are highly dependent on interactions with the immunosuppressive tumor microenvironment (TME) for survival and proliferation. In the search for novel treatments, pro-inflammatory cytokines have emerged...
6.
Faehling S, Coelho M, Floerchinger A, Schneider C, Stilgenbauer S, Lichter P, et al.
Hemasphere
. 2023 Feb;
7(3):e840.
PMID: 36844182
Chronic lymphocytic leukemia (CLL) is a common and incurable B-cell malignancy. Recent therapeutic approaches that target the B-cell receptor signaling pathway include inhibition of phosphatidylinositol-3-kinase (PI3K). The PI3K isoform delta...
7.
Hanna B, Llao-Cid L, Iskar M, Roessner P, Klett L, Wong J, et al.
Immunity
. 2021 Dec;
54(12):2825-2841.e10.
PMID: 34879221
T cell exhaustion limits anti-tumor immunity and responses to immunotherapy. Here, we explored the microenvironmental signals regulating T cell exhaustion using a model of chronic lymphocytic leukemia (CLL). Single-cell analyses...
8.
9.
Jebaraj B, Muller A, Dheenadayalan R, Endres S, Roessner P, Seyfried F, et al.
Blood
. 2021 Oct;
139(6):859-875.
PMID: 34662393
Covalent Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib, have proven to be highly beneficial in the treatment of chronic lymphocytic leukemia (CLL). Interestingly, the off-target inhibition of IL-2-inducible T-cell...
10.
Roider T, Brinkmann B, Kim V, Knoll M, Kolb C, Roessner P, et al.
Blood Adv
. 2021 Sep;
5(23):5060-5071.
PMID: 34587238
Bispecific antibodies (BsAbs) can induce long-term responses in patients with refractory and relapsed B-cell lymphoma. Nevertheless, response rates across patients are heterogeneous, and the factors determining quality and duration of...